Evaluation of significance of lymphocyte subpopulations and non-specific serologic markers in B-cell non-Hodgkin's lymphoma patients

Éva Pósfai, Gábor Irsai, A. Illés, G. Méhes, Imelda Marton, Csaba Molnár, I. Csípő, S. Baráth, L. Gergely

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The use of rituximab brought attention to the hosts' immune system and to the microenvironment in non-Hodgkin's lymphoma cases. Our aim was to identify prognostic factors that can be measured easily to indicate the current state of the patient's immune status and possible reaction against malignant cells. In the retrospective analysis (2000-2008), 66 patients diagnosed with B-cell non-Hodgkin's lymphomas were enrolled (40 women, 26 men; mean age: 51 years). White blood cells, lymphocytes, CD3 +; CD4 +; CD8 + T-cells, immunoglobulin types A; G; M, anti-cardiolipin antibody isotypes A; G; M; and levels of beta-2-microglobulin were measured before the initiation of the first cycle of chemotherapy, during and after 4-weeks treatment. As for CD 3+ T-lymphocytes, the absolute CD 3+ T -lymphocyte numbers were higher before (0.78 × 109/L) versus during (0.27 × 109/L) treatment, and increased percentages were detected in pre- (66.57 %) and post-treatment (75.32 %). Absolute numbers of CD 8+ T-lymphocyte levels showed reduction before (0.26 × 109/L) versus during (0.10 × 109/L) therapy, but were elevated after (0.28 × 109/L) treatment, while increased percentage before (21.99 %) versus after (29.85 %), and during (24.56 %) versus after (29.85 %) therapy were seen. Average white blood cell numbers were increased before (9.71 × 109/L) versus during (12.07 × 109/L) treatment, while decreased numbers could be observed, after (5.47 × 109/L) treatment. IgA levels were decreased before (2.51 g/L) versus after (1.63 g/L) therapy. IgG levels were higher before (12.25 g/L) vs. after (8.64 g/L) treatment. IgM levels were decreased before (1.76 g/L) and after (0.83 g/L) as well as before (1.76 g/L) versus during (0.73 g/L) treatment. Anti-cardiolipin antibody type A level were decreased before (2.76 U/ml) versus after (2.49 U/ml) treatment. Decreased level of beta-2-microglobulin could be observed before (2.91 mg/L) versus post (2.28 mg/L) chemotherapy. Findings may provide better insight into the effects of immuno-chemotherapy on the hosts' immune system.

Original languageEnglish
Pages (from-to)649-654
Number of pages6
JournalPathology and Oncology Research
Volume20
Issue number3
DOIs
Publication statusPublished - 2014

Fingerprint

Lymphocyte Subsets
B-Cell Lymphoma
Non-Hodgkin's Lymphoma
Therapeutics
T-Lymphocytes
beta 2-Microglobulin
Cardiolipins
Drug Therapy
Immunoglobulin A
Anti-Idiotypic Antibodies
Immune System
Leukocytes
Immunoglobulin G
Blood Cell Count
Lymphocyte Count
Immunoglobulin M
Lymphocytes

Keywords

  • Host immune system
  • Immuno-chemotherapy
  • Lymphocyte subpopulations
  • Non-Hodgkin's lymphoma
  • Non-specific serologic markers

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pathology and Forensic Medicine
  • Medicine(all)

Cite this

Evaluation of significance of lymphocyte subpopulations and non-specific serologic markers in B-cell non-Hodgkin's lymphoma patients. / Pósfai, Éva; Irsai, Gábor; Illés, A.; Méhes, G.; Marton, Imelda; Molnár, Csaba; Csípő, I.; Baráth, S.; Gergely, L.

In: Pathology and Oncology Research, Vol. 20, No. 3, 2014, p. 649-654.

Research output: Contribution to journalArticle

@article{1ca25616eae04e779f1209b29c773fc6,
title = "Evaluation of significance of lymphocyte subpopulations and non-specific serologic markers in B-cell non-Hodgkin's lymphoma patients",
abstract = "The use of rituximab brought attention to the hosts' immune system and to the microenvironment in non-Hodgkin's lymphoma cases. Our aim was to identify prognostic factors that can be measured easily to indicate the current state of the patient's immune status and possible reaction against malignant cells. In the retrospective analysis (2000-2008), 66 patients diagnosed with B-cell non-Hodgkin's lymphomas were enrolled (40 women, 26 men; mean age: 51 years). White blood cells, lymphocytes, CD3 +; CD4 +; CD8 + T-cells, immunoglobulin types A; G; M, anti-cardiolipin antibody isotypes A; G; M; and levels of beta-2-microglobulin were measured before the initiation of the first cycle of chemotherapy, during and after 4-weeks treatment. As for CD 3+ T-lymphocytes, the absolute CD 3+ T -lymphocyte numbers were higher before (0.78 × 109/L) versus during (0.27 × 109/L) treatment, and increased percentages were detected in pre- (66.57 {\%}) and post-treatment (75.32 {\%}). Absolute numbers of CD 8+ T-lymphocyte levels showed reduction before (0.26 × 109/L) versus during (0.10 × 109/L) therapy, but were elevated after (0.28 × 109/L) treatment, while increased percentage before (21.99 {\%}) versus after (29.85 {\%}), and during (24.56 {\%}) versus after (29.85 {\%}) therapy were seen. Average white blood cell numbers were increased before (9.71 × 109/L) versus during (12.07 × 109/L) treatment, while decreased numbers could be observed, after (5.47 × 109/L) treatment. IgA levels were decreased before (2.51 g/L) versus after (1.63 g/L) therapy. IgG levels were higher before (12.25 g/L) vs. after (8.64 g/L) treatment. IgM levels were decreased before (1.76 g/L) and after (0.83 g/L) as well as before (1.76 g/L) versus during (0.73 g/L) treatment. Anti-cardiolipin antibody type A level were decreased before (2.76 U/ml) versus after (2.49 U/ml) treatment. Decreased level of beta-2-microglobulin could be observed before (2.91 mg/L) versus post (2.28 mg/L) chemotherapy. Findings may provide better insight into the effects of immuno-chemotherapy on the hosts' immune system.",
keywords = "Host immune system, Immuno-chemotherapy, Lymphocyte subpopulations, Non-Hodgkin's lymphoma, Non-specific serologic markers",
author = "{\'E}va P{\'o}sfai and G{\'a}bor Irsai and A. Ill{\'e}s and G. M{\'e}hes and Imelda Marton and Csaba Moln{\'a}r and I. Cs{\'i}pő and S. Bar{\'a}th and L. Gergely",
year = "2014",
doi = "10.1007/s12253-014-9744-3",
language = "English",
volume = "20",
pages = "649--654",
journal = "Pathology and Oncology Research",
issn = "1219-4956",
publisher = "Springer Netherlands",
number = "3",

}

TY - JOUR

T1 - Evaluation of significance of lymphocyte subpopulations and non-specific serologic markers in B-cell non-Hodgkin's lymphoma patients

AU - Pósfai, Éva

AU - Irsai, Gábor

AU - Illés, A.

AU - Méhes, G.

AU - Marton, Imelda

AU - Molnár, Csaba

AU - Csípő, I.

AU - Baráth, S.

AU - Gergely, L.

PY - 2014

Y1 - 2014

N2 - The use of rituximab brought attention to the hosts' immune system and to the microenvironment in non-Hodgkin's lymphoma cases. Our aim was to identify prognostic factors that can be measured easily to indicate the current state of the patient's immune status and possible reaction against malignant cells. In the retrospective analysis (2000-2008), 66 patients diagnosed with B-cell non-Hodgkin's lymphomas were enrolled (40 women, 26 men; mean age: 51 years). White blood cells, lymphocytes, CD3 +; CD4 +; CD8 + T-cells, immunoglobulin types A; G; M, anti-cardiolipin antibody isotypes A; G; M; and levels of beta-2-microglobulin were measured before the initiation of the first cycle of chemotherapy, during and after 4-weeks treatment. As for CD 3+ T-lymphocytes, the absolute CD 3+ T -lymphocyte numbers were higher before (0.78 × 109/L) versus during (0.27 × 109/L) treatment, and increased percentages were detected in pre- (66.57 %) and post-treatment (75.32 %). Absolute numbers of CD 8+ T-lymphocyte levels showed reduction before (0.26 × 109/L) versus during (0.10 × 109/L) therapy, but were elevated after (0.28 × 109/L) treatment, while increased percentage before (21.99 %) versus after (29.85 %), and during (24.56 %) versus after (29.85 %) therapy were seen. Average white blood cell numbers were increased before (9.71 × 109/L) versus during (12.07 × 109/L) treatment, while decreased numbers could be observed, after (5.47 × 109/L) treatment. IgA levels were decreased before (2.51 g/L) versus after (1.63 g/L) therapy. IgG levels were higher before (12.25 g/L) vs. after (8.64 g/L) treatment. IgM levels were decreased before (1.76 g/L) and after (0.83 g/L) as well as before (1.76 g/L) versus during (0.73 g/L) treatment. Anti-cardiolipin antibody type A level were decreased before (2.76 U/ml) versus after (2.49 U/ml) treatment. Decreased level of beta-2-microglobulin could be observed before (2.91 mg/L) versus post (2.28 mg/L) chemotherapy. Findings may provide better insight into the effects of immuno-chemotherapy on the hosts' immune system.

AB - The use of rituximab brought attention to the hosts' immune system and to the microenvironment in non-Hodgkin's lymphoma cases. Our aim was to identify prognostic factors that can be measured easily to indicate the current state of the patient's immune status and possible reaction against malignant cells. In the retrospective analysis (2000-2008), 66 patients diagnosed with B-cell non-Hodgkin's lymphomas were enrolled (40 women, 26 men; mean age: 51 years). White blood cells, lymphocytes, CD3 +; CD4 +; CD8 + T-cells, immunoglobulin types A; G; M, anti-cardiolipin antibody isotypes A; G; M; and levels of beta-2-microglobulin were measured before the initiation of the first cycle of chemotherapy, during and after 4-weeks treatment. As for CD 3+ T-lymphocytes, the absolute CD 3+ T -lymphocyte numbers were higher before (0.78 × 109/L) versus during (0.27 × 109/L) treatment, and increased percentages were detected in pre- (66.57 %) and post-treatment (75.32 %). Absolute numbers of CD 8+ T-lymphocyte levels showed reduction before (0.26 × 109/L) versus during (0.10 × 109/L) therapy, but were elevated after (0.28 × 109/L) treatment, while increased percentage before (21.99 %) versus after (29.85 %), and during (24.56 %) versus after (29.85 %) therapy were seen. Average white blood cell numbers were increased before (9.71 × 109/L) versus during (12.07 × 109/L) treatment, while decreased numbers could be observed, after (5.47 × 109/L) treatment. IgA levels were decreased before (2.51 g/L) versus after (1.63 g/L) therapy. IgG levels were higher before (12.25 g/L) vs. after (8.64 g/L) treatment. IgM levels were decreased before (1.76 g/L) and after (0.83 g/L) as well as before (1.76 g/L) versus during (0.73 g/L) treatment. Anti-cardiolipin antibody type A level were decreased before (2.76 U/ml) versus after (2.49 U/ml) treatment. Decreased level of beta-2-microglobulin could be observed before (2.91 mg/L) versus post (2.28 mg/L) chemotherapy. Findings may provide better insight into the effects of immuno-chemotherapy on the hosts' immune system.

KW - Host immune system

KW - Immuno-chemotherapy

KW - Lymphocyte subpopulations

KW - Non-Hodgkin's lymphoma

KW - Non-specific serologic markers

UR - http://www.scopus.com/inward/record.url?scp=84904127487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904127487&partnerID=8YFLogxK

U2 - 10.1007/s12253-014-9744-3

DO - 10.1007/s12253-014-9744-3

M3 - Article

C2 - 24488335

AN - SCOPUS:84904127487

VL - 20

SP - 649

EP - 654

JO - Pathology and Oncology Research

JF - Pathology and Oncology Research

SN - 1219-4956

IS - 3

ER -